What is the degree of steroid-sparing effect that can be anticipated when using ECP to treat GVHD? And what complications should be considered to be part of an ECP-dominant treatment strategy for GVHD?

What is the degree of steroid-sparing effect that can be anticipated when using ECP to treat GVHD? And what complications should be considered to be part of an ECP-dominant treatment strategy for GVHD?

CLICK HERE FOR CME CREDIT

What is the degree of steroid-sparing effect that can be anticipated when using ECP to treat GVHD? And what complications should be considered to be part of an ECP-dominant treatment strategy for GVHD?

Created by

CMEducation Resources IQ&A Extracorporeal Photopheresis Intelligence Zone | The Multi-Specialty Perspective

Presenter

Daniel Couriel, MD, MS

Daniel Couriel, MD, MS

Daniel R. Couriel, MD, MS
Professor of Internal Medicine
Director, Huntsman Cancer Institute (HCI) Blood and Marrow Transplant Program
University of Utah School of Medicine
Salt Lake City, UT